摘要
【目的】4g讨阿托伐他汀对冠脉介入治疗（PCI）术后血清高敏C反应蛋白（hs-CRP）和单核细胞过氧化物酶增殖体激活型受体γ（PPARγ）的影响。【方法】接受PCI的98例急性冠状动脉综合征（ACS）患者，随机分为治疗组和对照组；分别给予阿托伐他汀钙片40mg（49例）和10mg（49例）每晚口服。于术前及术后24h，10d测定血清高敏C反应蛋白（hs-CRP）和单核细胞过氧化物酶增殖体激活型受体γ（PPARγ）水平。酶联免疫吸附法：（ELSA）检测：hs－CRP与PPARγ。【结果】①两组hs－CRP水平术后24h升高（均P〈0．01），术后10d低于术后24h（均P〈0．01），治疗组下降更显著，恢复到术前水平。②两组PPARγ水平术后24h升高（均P〈0．01），术后10d进一步升高（均P〈0．01），治疗组明高于对照组（P〈0．01）。③两组hs－CRP／PPAR7比值术后24h升高（均P〈0．01），术后10d下降（均P〈0．01），治疗组较对照组下降更显著（P〈0．01）。【结论】ACS患者PCI使用大剂量阿托伐他汀能促进hsCRP、hs—CRP／PPARγ下降和PPARγ水平升高。
[Objective]To investigate the effects of atorvastatin on serum high sensitivity C reactive protein （hs-CRP） and peroxisome proliferator-activated receptor-gamma （PPARγ） in patients with acute coronary syndrome （ACS） after percutaneous transluminal coronary intervention （PCI）. [Methods] A total of 98 patients with ACS after PCI were divided into the treatment group （ n =49） and control group（ n =49）, orally taking atorvastatin calcium tablet 40rag or 10mg, respectively. The concentration of hs-CRP and PPARγ were measured by ELISA before and after 24h and 10d. [Results] Serum hs CRP level in two groups increased at 24h and decreased significantly at 10d after PCI（ P 〈0.01）, especially in treatment group. In two groups, the level of PPAR7 increased at 24 h and continued to rise until 10d after PCI, especially in treatment group. The hs-CRP/PPARγ ratio was higher at 24h after PCI and lower at 10d after PCI in treatment group than that in control group（ P〈0.01）. [Conclusion]Taking large dosage of atorvastatin can decrease hs-CRP level and hs-CRP/PPARγ ratio, and increase PPARγ in patients with ACS after PCI.
出处
《医学临床研究》
CAS
2009年第12期2229-2232,共4页
Journal of Clinical Research
